For investor-related information please contact Ronn Bechler at Automic Group Ph: +61 (0) 400 009 774 E: ronn.bechler@automicgroup.com.au
Zelira to launch a suite of new cannabinoid-based products in FY22 – Proactive
Zelira Therapeutics and Curtin University partner on research of proprietary technology that demonstrates significant uptake of CBD into the brain
Zelira Therapeutics Investor Slide Deck
Zelira Chairman Presentation at Cantor Fitzgerald International Cannabis Forum
Talking about the upcoming chronic pain clinical trial
Zelira Therapeutics are well positioned for ‘multiple product launches in 2021’
Start typing and press Enter to search